LifeSci Capital Initiates Coverage of TetraLogic Pharmaceuticals Corporation

Developing therapies for Oncology and Infectious Diseases; Report Available here: http://www.lifescicapital.com/equity-research/tetralogic/

NEW YORK, NY / ACCESSWIRE / December 31, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of TetraLogic Pharmaceuticals (Nasdaq: TLOG), a clinical-stage biopharmaceutical company developing therapies for cancer and infectious diseases. The Company is developing birinapant, a second generation SMAC-mimetic for the treatment of myelodysplastic syndromes (MDS) and hepatitis B virus (HBV). The Company’s second product candidate is SHAPE, a topical HDAC inhibitor for the treatment of early stage cutaneous T-cell lymphoma (CTCL).

MDS affects approximately 60,000 individuals in the US. Prognosis for patients with higher-risk MDS is poor, with a 3-year survival rate of just 42%. TetraLogic is developing birinapant in combination with the standard of care azacitidine for first-line higher-risk MDS patients with the goal of improving the response rate and thus longer term outcomes including progression-free survival (PFS) and overall survival (OS). Birinapant has demonstrated initial signs of efficacy in a Phase Ib and a Phase IIa study. A randomized Phase II study is ongoing, with interim results expected in January 2016.

TetraLogics is also developing SHAPE, a topical HDAC inhibitor, for the treatment of early stage CTCL, which affects approximately 30,000 individuals in North America. The efficacy of HDAC inhibitors as systemic therapy for CTCL is well-established, although it is important to note that dose-limiting toxicities hamper their use in early stages of the disease. TetraLogic’s topical HDACi SHAPE is designed to maximize activity in the skin and limit systemic exposure by rendering the drug inactive in the presence of endogenous serum esterases. Interim results from a randomized Phase II study are expected in January 2016.

In a 50 page Initiation Report LifeSci Capital explains the unmet medical need for MDS, birinapant’s mechanism of action, and the market opportunity upon a potential FDA approval. The report also highlights the opportunity for SHAPE in CTCL.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on TetraLogic as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 435242